Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Comment by Jonnyboy85on Oct 14, 2020 5:23pm
149 Views
Post# 31718239

RE:RE:RE:RE:RE:RE:Don’t get shaken out!

RE:RE:RE:RE:RE:RE:Don’t get shaken out!Oh ya completely agree with just about every contribution on the whole thread. My forcast of north of 0.20 is preconsolidation. It would work out to $1.60 and would be a good starting point moving through q4


Northerencents wrote: I once again disagree lol, 2$ would give us a 100,000,000 market cap our forecasted revenue should easily give us 200 million market cap although it could take us another quarter to prove the upward and consistent trajectory!

if some gravy buzz featuring Aristotle comes out along with q3 numbers 4$ is not far fetched aiming for 1-2$ is pretty low end to me 


<< Previous
Bullboard Posts
Next >>